Heska Corporation (NASDAQ:HSKA) has earned a consensus rating of “Hold” from the seven analysts that are covering the company, MarketBeat reports. Four analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The average 1 year price target among analysts that have updated their coverage on the stock in the last year is $105.20.

Several analysts have weighed in on the stock. B. Riley reiterated a “neutral” rating and set a $96.50 target price on shares of Heska Corporation in a research note on Thursday, August 3rd. BidaskClub lowered shares of Heska Corporation from a “buy” rating to a “hold” rating in a research note on Sunday, July 16th. Aegis boosted their target price on shares of Heska Corporation from $114.50 to $129.50 and gave the company a “buy” rating in a research note on Tuesday, August 1st. Zacks Investment Research upgraded shares of Heska Corporation from a “hold” rating to a “buy” rating and set a $109.00 target price for the company in a research note on Friday, August 4th. Finally, Benchmark Co. restated a “buy” rating and set a $120.00 price target (up previously from $106.00) on shares of Heska Corporation in a research report on Wednesday, August 9th.

WARNING: This report was originally posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this report on another domain, it was illegally copied and republished in violation of United States & international trademark and copyright law. The original version of this report can be viewed at https://www.thecerbatgem.com/2017/08/26/heska-corporation-hska-receives-105-20-average-price-target-from-brokerages.html.

In other news, EVP Steve Asakowicz sold 382 shares of the company’s stock in a transaction dated Thursday, June 1st. The shares were sold at an average price of $100.08, for a total transaction of $38,230.56. Following the completion of the transaction, the executive vice president now owns 10,382 shares in the company, valued at $1,039,030.56. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Rod Lippincott sold 11,227 shares of the company’s stock in a transaction dated Wednesday, May 31st. The stock was sold at an average price of $98.00, for a total transaction of $1,100,246.00. Following the transaction, the executive vice president now owns 11,292 shares of the company’s stock, valued at approximately $1,106,616. The disclosure for this sale can be found here. Insiders have sold 22,798 shares of company stock valued at $2,240,929 in the last 90 days. Insiders own 14.70% of the company’s stock.

Several institutional investors have recently added to or reduced their stakes in HSKA. Teachers Advisors LLC raised its position in Heska Corporation by 4.0% in the fourth quarter. Teachers Advisors LLC now owns 9,493 shares of the medical research company’s stock valued at $680,000 after buying an additional 364 shares in the last quarter. Louisiana State Employees Retirement System purchased a new position in Heska Corporation during the first quarter valued at approximately $262,000. Acadian Asset Management LLC raised its position in Heska Corporation by 54.2% in the first quarter. Acadian Asset Management LLC now owns 95,300 shares of the medical research company’s stock valued at $10,005,000 after buying an additional 33,498 shares in the last quarter. Riverbridge Partners LLC raised its position in Heska Corporation by 257.0% in the first quarter. Riverbridge Partners LLC now owns 244,031 shares of the medical research company’s stock valued at $25,618,000 after buying an additional 175,674 shares in the last quarter. Finally, Russell Investments Group Ltd. raised its position in Heska Corporation by 11.1% in the first quarter. Russell Investments Group Ltd. now owns 190,794 shares of the medical research company’s stock valued at $20,030,000 after buying an additional 18,996 shares in the last quarter. Institutional investors and hedge funds own 79.81% of the company’s stock.

Heska Corporation (NASDAQ HSKA) traded down 3.25% on Wednesday, reaching $95.80. 31,558 shares of the company were exchanged. The stock has a market capitalization of $692.25 million, a price-to-earnings ratio of 48.83 and a beta of 0.82. The stock has a 50-day moving average price of $100.94 and a 200 day moving average price of $97.17. Heska Corporation has a 52 week low of $46.51 and a 52 week high of $115.00.

Heska Corporation (NASDAQ:HSKA) last released its earnings results on Thursday, August 3rd. The medical research company reported $0.44 earnings per share for the quarter, beating the consensus estimate of $0.37 by $0.07. Heska Corporation had a net margin of 10.70% and a return on equity of 15.87%. The firm had revenue of $34.30 million during the quarter, compared to analyst estimates of $33.35 million. During the same quarter in the previous year, the firm earned $0.35 earnings per share. The firm’s revenue for the quarter was up 14.3% compared to the same quarter last year. Analysts forecast that Heska Corporation will post $2.04 earnings per share for the current year.

About Heska Corporation

Heska Corporation sells veterinary diagnostic and specialty products. The Company operates through two segments: Core Companion Animal Health (CCA) and Other Vaccines, Pharmaceuticals and Products (OVP). The CCA segment includes, primarily for canine and feline use, blood testing instruments and supplies, digital imaging products, software and services, local and cloud-based data services, allergy testing and immunotherapy, and single use offerings, such as in-clinic diagnostic tests and heartworm preventive products.

Analyst Recommendations for Heska Corporation (NASDAQ:HSKA)

Receive News & Stock Ratings for Heska Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heska Corporation and related stocks with our FREE daily email newsletter.